Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has 3 years of Current Deferred Revenue data on file, last reported at $669996.8 in Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $669996.8, up 23.88% year-over-year; the trailing twelve-month figure through Dec 2025 was $669996.8 (up 23.88% YoY), and the FY2025 annual result was $11000.0, down 97.69% from the prior year.
• Current Deferred Revenue grew to $669996.8 in Q4 2025 per ZYBT's latest filing, from $140000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $669996.8 in Q4 2025 and troughed at $140000.0 in Q2 2025.
• A 3-year average of $497467.7 and a median of $589937.0 in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue fell 15.36% in 2024, then rose 23.88% in 2025.
• A 3-year view of Current Deferred Revenue shows it stood at $639020.9 in 2023, then fell by 15.36% to $540853.1 in 2024, then grew by 23.88% to $669996.8 in 2025.
• Business Quant data shows ZYBT's Current Deferred Revenue at $669996.8 in Q4 2025, $140000.0 in Q2 2025, and $540853.1 in Q4 2024.